نتایج جستجو برای: pharmacokinetic study

تعداد نتایج: 3982380  

2016
Lingzhi Wang Do Dang Khoa Phan Jingwen Zhang Pei-Shi Ong Win Lwin Thuya Ross Soo Andrea Li-Ann Wong Wei Peng Yong Soo Chin Lee Paul Chi-Lui Ho Gautam Sethi Boon Cher Goh

Nimbolide is one of the main components in the leaf extract of Azadirachta indica (A. indica). Accumulating evidence from various in vitro and in vivo studies indicates that nimbolide possesses potent anticancer activity against several types of cancer and also shows potential chemopreventive activity in animal models. The main mechanisms of action of nimbolide include anti-proliferation, induc...

Journal: :Antimicrobial agents and chemotherapy 2011
Masanori Kobayashi Tomokazu Yoshinaga Takahiro Seki Chiaki Wakasa-Morimoto Kevin W Brown Robert Ferris Scott A Foster Richard J Hazen Shigeru Miki Akemi Suyama-Kagitani Shinobu Kawauchi-Miki Teruhiko Taishi Takashi Kawasuji Brian A Johns Mark R Underwood Edward P Garvey Akihiko Sato Tamio Fujiwara

S/GSK1349572 is a next-generation HIV integrase (IN) inhibitor designed to deliver potent antiviral activity with a low-milligram once-daily dose requiring no pharmacokinetic (PK) booster. In addition, S/GSK1349572 demonstrates activity against clinically relevant IN mutant viruses and has potential for a high genetic barrier to resistance. S/GSK1349572 is a two-metal-binding HIV integrase stra...

2011
Andreas Steingoetter Dieter Menne Rickmer F. Braren

Dynamic contrast enhanced (DCE-) MRI is commonly applied for the monitoring of antiangiogenic therapy in oncology. Established pharmacokinetic (PK) analysis methods of DCE-MRI data do not sufficiently reflect the complex anatomical and physiological constituents of the analyzed tissue. Hence, accepted endpoints such as Ktrans reflect an unknown multitude of local and global physiological effect...

Journal: :Antiviral therapy 2013
Jessica L Adams Kristine B Patterson Heather M A Prince Craig Sykes Benjamin N Greener Julie B Dumond Angela D M Kashuba

BACKGROUND Antiretrovirals that achieve adequate concentrations in anatomical sites of transmission are of interest for HIV prevention. A Phase I open-label pharmacokinetic (PK) study was performed to describe first dose (PK1) and steady-state (PK2) PKs of the integrase inhibitor dolutegravir (DTG) in blood plasma (BP), cervicovaginal fluid (CVF), cervical tissue (CT) and vaginal tissue (VT) in...

Journal: :Antimicrobial agents and chemotherapy 2009
Natella Rakhmanina John van den Anker Aline Baghdassarian Steven Soldin Keetra Williams Michael N Neely

In adult protease inhibitor (PI)-experienced patients, a lopinavir (LPV) phenotypic inhibitory quotient (PIQ) of >15 has been associated with a higher likelihood of viral suppression. The aims of this study were to develop a population pharmacokinetic (PK) model of LPV in children and to estimate the probability of achieving a PIQ of >15. HIV-infected, PI-experienced children receiving LPV were...

2011
Joseph V. Pergolizzi Tong J. Gan Stanford Plavin Sumedha Labhsetwar Robert Taylor

Monitored anesthesia care (MAC) is a safe, effective, and appropriate form of anesthesia for many minor surgical procedures. The proliferation of outpatient procedures has heightened interest in MAC sedation agents. Among the most commonly used MAC sedation agents today are benzodiazepines, including midazolam, and propofol. Recently approved in the United States is fospropofol, a prodrug of pr...

2014
Lidia Savi Selene Mogavero Colin Gerard Egan

BACKGROUND Migraine is a painful neurological disorder that affects over 10% of the general population. Frovatriptan and rizatriptan are antimigraine agents belonging to the triptan class. Although previous studies have independently compared the efficacy of these agents, contemporaneous data examining both pharmacokinetic (PK) properties and efficacy in parallel have not previously been availa...

2017
Primal Kaur Vincent Chow Nan Zhang Michael Moxness Arunan Kaliyaperumal Richard Markus

OBJECTIVE To demonstrate pharmacokinetic (PK) similarity of biosimilar candidate ABP 501 relative to adalimumab reference product from the USA and European Union (EU) and evaluate safety, tolerability and immunogenicity of ABP 501. METHODS Randomised, single-blind, single-dose, three-arm, parallel-group study; healthy subjects were randomised to receive ABP 501 (n=67), adalimumab (USA) (n=69)...

Journal: :Investigative ophthalmology & visual science 2005
Jacques Gaudreault David Fei Jeriza Rusit Pamela Suboc Vanessa Shiu

PURPOSE Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in neovascular age-related macular degeneration. This study evaluated the pharmacokinetic (PK) and serum bioavailability of ranibizumab after a single intravitreal (ITV) or intravenous ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید